Guardant Health, Inc. announced it will present data highlighting the clinical utility of its liquid biopsy tests in the treatment and management of early- to late-stage gastrointestinal cancers, including colorectal cancer, at the 2022 ASCO Gastrointestinal Cancers Symposium being held January 20-22, 2022. An interim analysis from COSMOS-CRC-01, a large, prospective, observational study, shows that the Guardant Reveal™ liquid biopsy test, when performed after curative intent surgery for stage II-III colorectal cancer, can detect molecular residual disease (MRD) prior to disease recurrence with an average lead time of greater than six months. The test integrates genomic and epigenomic signatures to detect disease without the need for tumor tissue.

Additionally, clinical utility data will demonstrate that the Guardant360® liquid biopsy test detects microsatellite instability-high (MSI-H) status in patients with advanced gastrointestinal cancers at a similar frequency to tissue-based testing. MSI-H is an important biomarker used to predict response to immunotherapy. Also, real-world clinical outcomes data from the GuardantINFORM™ platform showed that colorectal cancer patients who received immune checkpoint blockade therapy after MSI-H status identification with Guardant360 achieved responses in line with published data in previously treated MSI-H advanced gastrointestinal cancers.